WASHINGTON – Patients, clinicians and families facing uncertainty about their choices for managing Type 2 diabetes and rare diseases will gain new evidence to inform their decision making from comparative clinical effectiveness research (CER) studies that the Patient-Centered Outcomes Research Institute (PCORI) Board of Governors today approved for a total...
finance News
Los Angeles, Calif. – The Pediatric Cancer Research Foundation today announced a call for entries for its 2024 Cancer Survivor Scholarships. The Foundation will award $100,000 to eligible students – including graduating high school seniors, college, vocational and graduate students – to support these students in realizing happy, productive futures....
Boston — PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, reported financial results for the fourth quarter and full year ended December 31, 2022 and highlighted recent corporate developments. “2022...
Pfizer has agreed to acquire Seagen, a global biotech focused on developing cancer treatments, for $43 billion. The announcement comes just a couple of weeks after the Wall Street Journal reported that the two companies were in talks. Both boards have approved the transaction, which is expected to close in...
Madrid – PharmaMar (MSE: PHM) has announced today a new license and commercialization agreement with the Eczacıbaşı Pharmaceuticals Marketing Co. to commercialize the anticancer drug lurbinectedin in Turkey. Under the terms of the agreement, PharmaMar will receive a non-disclosed upfront payment and will be eligible for additional remunerations, including regulatory...
WATERTOWN, Mass. – PlateletBio, a preclinical-stage biotechnology company pioneering an entirely new platform of allogeneic cell therapies based on platelet biology, today announced that it has raised $75.5 million in Series B financing. The round includes new investors SymBiosis, K2 HealthVentures and Oxford Finance as well as participation from existing...
NIJMEGEN, Netherlands – Pleco Therapeutics BV, a specialty biopharmaceutical company developing novel combination chelating agents to detoxify the cancer micro-environment today announces that it has entered into a strategic partnership with Hyloris Pharmaceuticals SA (Euronext Brussels: HYL), a specialty biopharma company committed to addressing unmet medical needs through reinventing existing medications, to...
Poland will spend over PLN 700 million (EUR 154.8 million) in 2021-2023 to cure rare diseases as a part of the Rare Disease Plan, the health minister has announced on Monday. Currently, the Plan defines 40 specific tasks and deadlines for their implementation, worth over PLN 90 million (EUR 19.8...
LONDON, UK – Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, announces that it has entered into an exclusive 12-month option agreement with Silk Road Therapeutics Inc, for a nominal fee, to acquire a novel...
SAN DIEGO, CA — Poseida Therapeutics, Inc., a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today highlighted recent progress across the company’s cell and gene therapy portfolio and provided updates on anticipated upcoming milestones. “In 2023, we made...